# Euglycemic Diabetic Ketoacidosis Triggered by Sepsis in a Patient on Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor Therapy: A Case of Diagnostic and Therapeutic Challenges

**Authors:** Archana Ramalingam, Ayele Tewadros, Bruno De Souza Goncalves, Anitha Yelangi, Ashraf Elghul

PMC · DOI: 10.7759/cureus.87029 · Cureus · 2025-06-30

## TL;DR

A patient on SGLT2 inhibitors developed euglycemic diabetic ketoacidosis complicated by sepsis, requiring urgent multidisciplinary care for recovery.

## Contribution

Highlights diagnostic and therapeutic challenges of EDKA in sepsis patients on SGLT2 inhibitors.

## Key findings

- EDKA can occur with mild hyperglycemia and sepsis in SGLT2 inhibitor users.
- Multidisciplinary management improves outcomes in complex EDKA cases.
- Early recognition of EDKA is critical for timely treatment.

## Abstract

Euglycemic diabetic ketoacidosis (EDKA) is an uncommon life-threatening condition increasingly recognized in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Its diagnosis is often delayed due to the absence of significant hyperglycemia. Sepsis can further complicate the clinical scenario, enhancing insulin resistance and promoting ketoacidosis. We report the case of a 69-year-old male with a history of diabetes mellitus managed with insulin, semaglutide, and empagliflozin, who presented with syncope, bradycardia, and gastrointestinal symptoms following antibiotic treatment for a lower extremity infection. Laboratory findings revealed high anion gap metabolic acidosis, lactic acidosis, mild hyperglycemia, and methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Despite unremarkable imaging, suspicion for EDKA was heightened due to severe metabolic derangements and the patient’s SGLT2 inhibitor use. Multidisciplinary management included aggressive fluid resuscitation, insulin therapy, empirical antibiotic coverage with vancomycin, and surgical debridement of a subsequently identified foot abscess. Clinical improvement paralleled the resolution of metabolic acidosis and bacteremia. This case highlights the critical need for early recognition of EDKA in patients on SGLT2 inhibitors, particularly in sepsis. Timely diagnosis, prompt management of underlying infections, and a multidisciplinary approach are essential for favorable outcomes.

## Linked entities

- **Chemicals:** empagliflozin (PubChem CID 11949646), semaglutide (PubChem CID 56843331), vancomycin (PubChem CID 14969)
- **Diseases:** diabetes mellitus (MONDO:0005015)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}, GCG (glucagon) [NCBI Gene 2641] {aka GLP-1, GLP1, GLP2, GRPP}
- **Diseases:** bacteremia (MESH:D016470), type 2 diabetes mellitus (MESH:D003924), gastrointestinal symptoms (MESH:D012817), bradycardia (MESH:D001919), dyspnea (MESH:D004417), organ dysfunction (MESH:D009102), DKA (MESH:D016883), glycosuria (MESH:D006029), Diabetes (MESH:D003920), lactic acidosis (MESH:D000140), renal dysfunction (MESH:D007674), bacterial infection (MESH:D001424), critically (MESH:D016638), oliguria (MESH:D009846), crackles (MESH:D012135), syncope (MESH:D013575), Infectious Disease (MESH:D003141), infective endocarditis (MESH:D004696), hypotension (MESH:D007022), inflammation (MESH:D007249), tachypnea (MESH:D059246), infection (MESH:D007239), insulin resistance (MESH:D007333), leukocytosis (MESH:D007964), MRSA (MESH:D013203), acidosis (MESH:D000138), fever (MESH:D005334), tachycardia (MESH:D013610), hyperglycemia (MESH:D006943), cough (MESH:D003371), pneumonia (MESH:D011014), Sepsis (MESH:D018805), ketoacidosis (MESH:D007662), abscess (MESH:D000038)
- **Chemicals:** creatinine (MESH:D003404), SGLT2 inhibitor (-), metformin (MESH:D008687), glucose (MESH:D005947), potassium (MESH:D011188), ketone bodies (MESH:D007657), bicarbonate (MESH:D001639), oxygen (MESH:D010100), pO2 (MESH:C093415), sodium (MESH:D012964), insulin (MESH:D007328), vancomycin (MESH:D014640), ceftriaxone (MESH:D002443), metoprolol (MESH:D008790), lactic acid (MESH:D019344), methicillin (MESH:D008712), Empagliflozin (MESH:C570240), Ketone (MESH:D007659)
- **Species:** Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280]
- **Mutations:** A1C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12309426/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12309426/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12309426/full.md

---
Source: https://tomesphere.com/paper/PMC12309426